Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Feb 28, 2023 4:52pm
92 Views
Post# 35310891

RE:RE:HFS and the CC

RE:RE:HFS and the CC

Meeting Marathon's financial and regulatory conditions in order to release $100 millions were  the only collateral towards the loan the company could offer and I believe that's why they agreed to it. If the drug isn't used correctly it is unsafe so complying with the FDA's requirements is a must to do. Marathon's concern as a lender is those financial projections are achievable any regulatory hurdles for the drug will jeopardize those projections  Unless the company don't submits the HFS in time which is unlikely it should be accepted as it is only about proper training. 

Point is they didn't anticipate any delays on the contrary they thought they could easily meet the timeline for the regulatory conditions both the HFS and F8's approval by March 2024 but it seems as for HFS's submission's deadline it might be an issue as per the PR today so Marathon took advantage of the situation and stick it in as far as it goes which is what lenders to if they can. Again no collateral only financial projections based on among others much more user friendly drug which improves the odds for better future sales.



palinc2000 wrote:

We may criticize the company for the slow progress but that was an educated guess which didn't materialize but not for pure stupidity agreeing to the conditions knowing they can't fulfill them.

From todays CC:

Granted but they still agreed on something they apparently had no control over!!! As a pre condition to drawing the 2 nd tranche needed to be bable to repay the freaking Convert...Why was that incorporated in the loan agreement if the delay per se is no big deal ?  There was nothing in todays PR and CC about the impact on sales of not having the HFS submiyyrd on time

Why did Marathon require that as a pre condition? 
Why did Cantor mention that the amendment removes an overhang that nobody knew anything about ? THTX never mentioned that there was a delay


 

<< Previous
Bullboard Posts
Next >>